For mutations in the tumors, patient groups 1 (Supplementary Figure 4A) and 2 (Supplementary Figure 4B) were more affected by signature 13 (most common in cervical and bladder cancers, attributed to the activity of the AID/APOBEC family), patient group 3 by signature 1 (endogenous mutational process initiated by spontaneous deamination of 5-methylcytosine) (Supplementary Figure 4C), and patient group 4 by signature 6 (defective DNA mismatch repair) (Supplementary Figure 4D). The gene discussed is AICDA; the disease is urinary bladder carcinoma.